10.42
-0.18(-1.70%)
Currency In USD
| Previous Close | 10.6 |
| Open | 10.58 |
| Day High | 10.77 |
| Day Low | 10.41 |
| 52-Week High | 13.06 |
| 52-Week Low | 9.76 |
| Volume | 4.44M |
| Average Volume | 4.74M |
| Market Cap | 7.44B |
| PE | -10.42 |
| EPS | -1 |
| Moving Average 50 Days | 10.91 |
| Moving Average 200 Days | 11.32 |
| Change | -0.18 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $1,001.92 as of March 13, 2025 at a share price of $10.42. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 3 years ago, it would be worth $2,092.37 as of March 13, 2025 at a share price of $10.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologicsNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zest Health, the first value-based virtual care company
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
GlobeNewswire Inc.
Jan 29, 2025 9:05 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
GlobeNewswire Inc.
Dec 03, 2024 12:00 PM GMT
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Ki